Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot to rule them all? new vaccine targets five meningococcal strains in infants

NCT ID NCT05082285

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new combination vaccine designed to protect healthy infants against five types of meningococcal bacteria (A, B, C, W, and Y) that can cause serious infections like meningitis. Over 700 infants received different doses or combinations of the vaccine to check safety and immune response. The goal is to see if this combined shot can offer broad protection with fewer injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Meningococcal combined ABCWY vaccine
What this could lead to
If successful, this vaccine could protect infants against five types of meningococcal bacteria with fewer shots, reducing the risk of serious infections like meningitis.
What could go wrong
This is an early phase 2 trial, so the vaccine may not prove effective enough or could cause side effects. Results in infants may differ from older age groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS, MENINGOCOCCAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIONS, MENINGOCOCCAL

Contacts and locations

Locations

  • GSK Investigational Site

    Santo Domingo Este, Dominican Republic

  • GSK Investigational Site

    Espoo, 02230, Finland

  • GSK Investigational Site

    Helsinki, 00100, Finland

  • GSK Investigational Site

    Jarvenpaa, 04400, Finland

  • GSK Investigational Site

    Kokkola, 67100, Finland

  • GSK Investigational Site

    Oulu, 90220, Finland

  • GSK Investigational Site

    Seinäjoki, 60100, Finland

  • GSK Investigational Site

    Gilching, 82205, Germany

  • GSK Investigational Site

    Schönau am Königssee, 83471, Germany

  • GSK Investigational Site

    San Pedro Sula, 21101, Honduras

  • GSK Investigational Site

    Bydgoszcz, 85-048, Poland

  • GSK Investigational Site

    Krakow, 30-348, Poland

  • GSK Investigational Site

    Krakow, 30-644, Poland

  • GSK Investigational Site

    Luboń, 62-030, Poland

  • GSK Investigational Site

    Siemianowice Śląskie, 41-103, Poland

  • GSK Investigational Site

    Torun, 87-100, Poland

  • GSK Investigational Site

    Trzebnica, 55-100, Poland

  • GSK Investigational Site

    Warsaw, 02-647, Poland

  • GSK Investigational Site

    Wroclaw, 50368, Poland

  • GSK Investigational Site

    Parow Valley, 7505, South Africa

  • GSK Investigational Site

    Soweto Gauteng, 2013, South Africa

  • GSK Investigational Site

    Almería, 04120, Spain

  • GSK Investigational Site

    Burgos, 09006, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

  • GSK Investigational Site

    Marbella, 29600, Spain

  • GSK Investigational Site

    Málaga, 29004, Spain

  • GSK Investigational Site

    Santiago de Compostela, 15706, Spain

  • GSK Investigational Site

    Seville, 41013, Spain

  • GSK Investigational Site

    Exeter, EX2 5DW, United Kingdom

  • GSK Investigational Site

    Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.